BIIB/ELN start phase-3b trial of Tysabri in secondary-progressing MS: http://finance.yahoo.com/news/ASCEND-Study-Evaluate-bw-3633786559.html?x=0 Why this trial is characterized as phase-3b (rather than phase-3) is unclear insofar as there is no pending regulatory submission I know of in SPMS.